Clinical pharmacology and pharmacokinetics of levetiracetam

Frontiers in Neurology

Volumn 4 DEC, Issue , 2013, Pages

  Wright, Chanin ^a   Downing, Jana ^a   Mungall, Diana ^b   Khan, Owais ^c   Williams, Amanda ^a   Fonkem, Ekokobe ^a   Garrett, Darin ^d   Aceves, Jose ^a   Kirmani, Batool ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Epilepsy; Levetiracetam; Pharmacokinetics

Indexed keywords

ETIRACETAM;

AMNESIA; ANOREXIA; ANXIETY DISORDER; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPERSENSITIVITY; INFECTION; IRRITABILITY; LOADING DRUG DOSE; MENTAL INSTABILITY; MOOD DISORDER; MYALGIA; NERVOUSNESS; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLEX DISORDER; RESTLESSNESS; REVIEW; RHINITIS; SEIZURE; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT OUTCOME; UNSTEADINESS; VERTIGO; WEAKNESS;

EID: 84891649144     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00192     Document Type: Review

References (43)

1. Keppra Injection (Levetiracetam) Package Insert. Smyrna, GA: UCB Pharma, Inc (2013).
2. Patsolos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet (2004) 43:707-24. doi:10.2165/00003088-200443110-00002.
3. Malik R, Sangwan A, Saihgal R, Kindal DP, Piplani P. Towards better brain management: nootropics. Curr Med Chem (2007) 14:123-31. doi:10.2174/092986707779313408.
4. Delanty N, Jones J, Tonner F. Adjunctive levetriacetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia (2012) 53:111-9. doi:10.1111/j.1528-1167.2011.03300.x.
5. Abend NS, Monk H, Licht DJ, Dlugos DJ. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med (2009) 10:505-10. doi:10.1097/PCC.0b013e3181a0e1cf.
6. Trinka E, Dobesberger J. New Treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord (2009) 2:79-91. doi:10.1177/1756285608100460.
7. Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy (2001) 21:1375-88. doi:10.1592/phco.21.17.1375.34432.
8. Depositario-Cabacar DT, Peters JM, Pong AW, Roth J, Rotenberg A, Viviello JJ Jr., et al. High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia (2010) 51:1319-22. doi:10.1111/j.1528-1167.2010.02519.x.
9. Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther (2006) 28:734-44. doi:10.1016/j.clinthera.2006.05.004.
10. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia (2006) 47:1128-35. doi:10.1111/j.1528-1167.2006.00586.x.
11. Leppik I, Goel V, Rarick J, Nixdorf D, Cloyd J. Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics. Epilepsy Res (2010) 91:289-92. doi:10.1016/j.eplepsyres.2010.07.016.
12. Wheless JW, Clarke D, Hovinga CA, Ellis M, Durmeier M, McGregor A, et al. Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. J Child Neurol (2009) 24:946-51. doi:10.1177/0883073808331351.
13. Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther (2005) 77:529-41. doi:10.1016/j.clpt.2005.02.003.
14. Tomson T, Palm R, Palm R, Kallen K, Ben-Menachem E, Soderfeldt B, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period and lactation. Epilepsia (2007) 48:1111-6. doi:10.1111/j.1528-1167.2007.01032.x.
15. Weinstock A, Ruiz M, Gerard D, Toublanc N, Stockis A, Farooq O, et al. Prospective open-label, single-arm, multicenter, safety, tolerability, and pharmacokinetic studies of intravenous levetiracetam in children with epilepsy. J Child Neurol (2013) 28:1423-9. doi:10.1177/0883073813480241.
16. Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T, et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr (2011) 159:152-4. doi:10.1016/j.jpeds.2011.03.057.
17. Ng YT, Hastriter EV, Cardenas JF, Khoury EM, Chapman KE. Intravenous levetiracetam in children with seizures: a prospective safety study. J Child Neurol (2010) 25:551-5. doi:10.1177/0883073809348795.
18. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia (2007) 48:1117-22. doi:10.1111/j.1528-1167.2007.01090.x.
19. Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia (2007) 48:2111-5. doi:10.1111/j.1528-1167.2007.01201.x.
20. Freitas-Lima P, Alexandre V Jr, Pereira LR, Feletti F, Perucca E, Sakamoto AC. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Res (2011) 94:117-20. doi:10.1016/j.eplepsyres.2011.01.007.
21. Aiguabella M, Falip M, Villanueva V, de la Penya P, Molins A, Garcia-Morales I, et al. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure (2011) 20:60-4. doi:10.1016/j.seizure.2010.10.009.
22. Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Clancy RR. Levetiracetam for the treatment of neonatal seizures. J Child Neurol (2011) 26:465-70. doi:10.1177/0883073810384263.
23. Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol (2011) 44:265-9. doi:10.1016/j.pediatrneurol.2010.11.005.
24. Michaelides C, Thibert RL, Shapiro MJ, Kinirons P, John T, Manchharam D, et al. Tolerability and dosing experience of intravenous levetiracetam in children and infants. Epilepsy Res (2008) 81:143-7. doi:10.1016/j.eplepsyres.2008.05.004.
25. Furwentsches A, Bussman C, Ramantani G, Ebinger F, Philippi H, Poschl J, et al. Levetiracetam in the treatment of neonatal seizures: a pilot study. Seizure (2010) 19:185-9. doi:10.1016/j.seizure.2010.01.003.
26. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol (2011) 15:1-7. doi:10.1016/j.ejpn.2010.10.003.
27. Li J, Xiao N, Chen S. Efficacy and tolerability of levetiracetam in children with epilepsy. Brain Dev (2011) 33:145-51. doi:10.1016/j.braindev.2010.03.002.
28. Kirmani BF, Crisp ED, Kayani S, Rajab H. Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol (2009) 41:37-9. doi:10.1016/j.pediatrneurol.2009.02.016.
29. Goraya JS, Khurana DS, Valencia I, Melvin JJ, Cruz M, Legido A, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol (2008) 38:177-80. doi:10.1016/j.pediatrneurol.2007.11.003.
30. Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav (2009) 14:215-8. doi:10.1016/j.yebeh.2008.09.028.
31. Khan O, Cipriani C, Wright C, Crisp E, Kirmani B. Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol (2013) 49:340-3. doi:10.1016/j.pediatrneurol.2013.05.008.
32. Aceves J, Khan O, Mungall D, Fonkem E, Wright C, Wenner A, et al. Efficacy and tolerability of intravenous levetiracetam in children. Front Neurol (2013) 4:120. doi:10.3389/fneur.2013.00120.
33. Kirmani BF. Acute seizure management in children. Pediatric Health (2009) 3:543-9. doi:10.2217/phe.09.59.
34. Liu YH, Wang XL, Deng YC, Zhao G. Levetiracetam-associated aggravation of myoclonic seizure in children. Seizure (2012) 21:807-9. doi:10.1016/j.seizure.2012.08.008.
35. Babtain FA. Levetiracetam may worsen myoclonus in patients with juvenile myoclonic epilepsy: case reports. Clin Neuropharmacol (2012) 35:201-2. doi:10.1097/WNF.0b013e31825eed8c.
36. Caraballo RH, Cersósimo R, De los Santos C. Levetiracetam-induced seizure aggravation associated with continuous spikes and waves during slow sleep in children with refractory epilepsies. Epileptic Disord (2010) 12:146-50. doi:10.1684/epd.2010.0305.
37. Auvin S, Chhun S, Berquin P, Ponchel E, Delanoë C, Chiron C. Aggravation of absence seizure related to levetiracetam. Eur J Paediatr Neurol (2011) 15:508-11. doi:10.1016/j.ejpn.2011.05.007.
38. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav (2003) 4:124-32. doi:10.1016/S1525-5050(03)00005-2.
39. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia (2001) 42:1611-3. doi:10.1046/j.1528-1157.2001.32101.x.
40. Youroukos S, Lazopoulou D, Michelakou D, Karagianni J. Acute psychosis associated with levetiracetam. Epileptic Disord (2003) 5:117-9.
41. Bayerlein K, Frieling H, Beyer B, Kornhuber J, Bleich S. Drug-induced psychosis after long-term treatment with levetiracetam. Can J Psychiatry (2004) 49:868.
42. Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav (2007) 11:130-2. doi:10.1016/j.yebeh.2007.04.008.
43. Givon L, Porter S, Padmanabhan B, Goren J, Cohen PA. Levetiracetam, seizures, and suicidality. Harv Rev Psychiatry (2011) 19:47-55. doi:10.3109/10673229.2011.549777.